(only available to AseBio members):

Startup Spotlight:

Investors will find deal flow opportunities by discovering promising startups showcased at the AseBio Investor Day. Uncover disruptive technologies and seize the opportunity to invest in the future.

PITCH to investment firms and potential collaborative partners from throughout Europe. 

Submit your application to present a start-up elevator pitch to international investors. This 6-minute dedicated session provides an opportunity to showcase your company’s business plan and latest products in development to a targeted audience, including public and private equity investors, as well as other biotech and pharmaceutical company executives. 

If you would like to become an AseBio member and present at the event, please contact us

  • At no extra cost of your registration fee.
  • Only available for AseBio Members.
  • Presentations will be delivered onsite on May 15th, 2024.
  • Not all applications will be accepted. A selection committee will review and accept or decline all applications*
  • Deadline to apply: February 29th, 2024

* Selection criteria: Business and company potential, Market attractiveness, Product/technology/IP merit, High international potential, Innovative business model, Strong entrepreneurial spirit, Attractiveness for investment, Competitive position.

Apply to present2022 Presenting Companies
Asebio Investor Day 2024

Apply to present

    Executive Summary

    I have read and accept the Terms and Conditions and the Privacy Policy.

    I accept receiving commercial information about AseBio and upcoming AseBio events.

    Check the 2022 edition Presenting companies.


    Area of Activity

    Ability Pharmaceuticals
    AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated cytotoxicity selectively in cancer cells.
    Allinky Biopharma SL
    Allinky is a biotechnology start-up founded in 2009 by an interdisciplinary group of leading scientists and led by an experienced team. Drug discovery and development company aiming at drugging difficult targets using allosteric inhibitors and protein-protein interaction inhibitors - in silico and in vitro company technology platform. Currently advancing two oral small molecules in the areas of inflammation (IL-1 beta and IL-6 production inhibitor) and oncology (Ras-related proliferation inhibitor)
    AON Therapeutics - CRG
    AON Therapeutics is a spin-off company from the CRG focused on developing first-in-class alternative splicing modifying antisense oligonucleotides for the treatment of lung cancer.
    Biohope Scientific Solutions
    Biohope Scientific Solutions is a biomedical company whose mission is to improve clinical outcomes in chronic inflammatory conditions by allowing the personalization and optimization of current and future immunosuppressant treatments.
    Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.
    Immuno Coaching
    We propose an Autologous T Cell Therapy (ACT) for acute leukemias based on re-activated Tumor-Specific Neoantigen/Antigen (TSA) T Cells with these unique selling proposition: A short vein-to-vein time of 7 days - Decentralized manufacturing at the point-of-care - Significantly lower cost of goods than current cell therapies - Predictive outcome using companion diagnostics. We’ve discovered a new way of coaching neoantigen & antigen T cells to reactivate and kill leukemic cells, showing similar activity as CAR Ts ex vivo.
    Inhibitec Anticuerpos S.L.
    Founded in 2019, spin-off CSIC and U. CAntabria. Inhibitec approach is a novel pathway to increase the efficacy vs current therapies for the treatment of Autoimmune diseases and more specifically on Psoriasis and Psoriatic Arthritis.
    Fundación Jiménez Díaz University Hospital Health Research Institute
    In addition to the hospital's clinical and care-related activity, the Fundación Jiménez Díaz University Hospital Health Research Institute has an established record of commitment to research and teaching. Health care, research, and teaching are the three pillars that guide the work carried out in the Institute (IIS—FJD, UAM), whose goal it is to drive excellence in research, scientific and technological understanding, and teaching and training. This mission informs the Institute's strategy, striving to bring advancement and research to clinical practice in the most efficient way possible.
    Inhibitec Anticuerpos S.L.
    Founded in 2019, spin-off CSIC and U. CAntabria. Inhibitec approach is a novel pathway to increase the efficacy vs current therapies for the treatment of Autoimmune diseases and more specifically on Psoriasis and Psoriatic Arthritis.
    Laminar Pharma
    A pioneering biopharmaceutical company, focused on the discovery, rational design and initial clinical development of drugs. These compounds are all based on a novel therapeutic approach: Membrane Lipid Therapy (MLT), or melitherapy for short, which targets membrane lipids, instead of acting directly on proteins or DNA as most medicines do.
    In MiMARK, we care for Women’s Health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients.
    MOA Foodtech
    Developer of sustainable foods designed to transform residues and by-products into high-value ingredients. The company processes include upcycling residues of the food industry to create high-value food, using the minimum amount of energy, water, and land as well as plant-based ingredients and substrates that are used in the process, enabling clients to eat healthily while reducing environmental impact and developing sustainable food that solves growing global food demands without the need for arable land and making healthy food for a sustainable world that solves growing global food demands.
    Nanoligent SL
    Nanoligent is a preclinical stage drug discovery company based in Barcelona, formally a spin-off of the Universitat Autònoma de Barcelona (UAB) and Hospital de Sant Pau. The company is focused on METASTASIS as an unmet clinical need, developing precision nanomedicines that selectively target metastatic CXCR4+ cancer cells in a subpopulation of cancer patients of several cancer types with very poor prognosis.
    Neurofix is a biotechnology company, focused on the research and development of innovative therapies for the treatment of pathologies related to the Central Nervous System. Its most advanced product in development is the drug NFX88, to treat neuropathic pain in patients with spinal cord injury, currently in the conclusion of a clinical trial Phase IIA study.
    Nucaps Nanotechnology
    Nucaps improves people’s health as we help to produce better food, supplements and drugs by making nutritional and bioactive ingredients and probiotics stable, easy to absorb, healthy and natural. We offer development services on nanoencapsulation with nutritional and medical purposes. We are experts in research, development, and manufacturing about encapsulation of active ingredients and probiotics with food proteins for Health and Nutritional purposes.
    Oniria Therapeutics, S.L.
    Oniria Therapeutics, S.L. is a biopharmaceutical company whose objective is the development of first-in-class precision oncology drugs to modulate cancer dormancy as a new treatment strategy to overcome cancer persistence. Oniria therapeutics is a spin-off company of the Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA) set-up on December 23rd, 2021.
    A quality-focused, scalable, cannabis cultivation and distribution company with the long-term vision of creating positive social impact by serving the pharmaceutical, wellness and lifestyle industries with high-grade dried flowers from truly exceptional cultivars grown sustainably using nature’s resources efficiently.
    Vaxdyn develops vaccines for prevention of infections by antibiotic-resistant bacteria in the high-risk populations. Our proprietary technology is able to deliver multi-pathogen vaccines able to neutralize infections by 4 of the 6 bacteria responsible for 73% of global deaths attributable to antimicrobial-resistance.

    Contact us